Cargando…
Review of Mavacamten for Obstructive Hypertrophic Cardiomyopathy and Future Directions
Hypertrophic cardiomyopathy (HCM) is a condition with abnormal hypertrophy of the left ventricle in the absence of common causes. The most common form involves the basal septum and can lead to obstruction of the left ventricular outflow tract. Patients can experience exertional symptoms such as ches...
Autores principales: | Dong, Tiffany, Alencherry, Ben, Ospina, Susan, Desai, Milind Y |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10094472/ https://www.ncbi.nlm.nih.gov/pubmed/37064432 http://dx.doi.org/10.2147/DDDT.S368590 |
Ejemplares similares
-
Alcohol Septal Ablation or Mavacamten for Obstructive Hypertrophic Cardiomyopathy
por: Scholtz, Smita, et al.
Publicado: (2023) -
Left ventricular outflow tract obstruction in hypertrophic
cardiomyopathy and the impact of mavacamten
por: Mathai, Susan, et al.
Publicado: (2022) -
Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy
por: Braunwald, Eugene, et al.
Publicado: (2023) -
The Impact of Mavacamten on the Pathophysiology of Hypertrophic Cardiomyopathy: A Narrative Review
por: Edelberg, Jay M., et al.
Publicado: (2022) -
The European Medicines Agency assessment of mavacamten as treatment of symptomatic obstructive hypertrophic cardiomyopathy in adult patients
por: DeVries, J Hans, et al.
Publicado: (2023)